Zogenix, Inc. (NASDAQ:ZGNX) major shareholder Life Sciences Maste Perceptive acquired 300,000 shares of the business’s stock in a transaction on Tuesday, October 3rd. The stock was purchased at an average cost of $37.50 per share, with a total value of $11,250,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Friday, September 29th, Life Sciences Maste Perceptive acquired 222,055 shares of Zogenix stock. The stock was purchased at an average cost of $32.83 per share, with a total value of $7,290,065.65.

Shares of Zogenix, Inc. (NASDAQ:ZGNX) opened at 39.20 on Thursday. The stock’s market cap is $973.77 million. Zogenix, Inc. has a 1-year low of $7.50 and a 1-year high of $41.65. The stock’s 50 day moving average is $16.21 and its 200-day moving average is $13.46.

Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.01). Zogenix had a negative net margin of 309.76% and a negative return on equity of 70.75%. The company had revenue of $7.10 million during the quarter, compared to analyst estimates of $3.48 million. During the same quarter last year, the business earned ($0.76) EPS. The firm’s revenue for the quarter was up 238.1% on a year-over-year basis. On average, analysts predict that Zogenix, Inc. will post ($3.66) EPS for the current fiscal year.

WARNING: “Life Sciences Maste Perceptive Buys 300,000 Shares of Zogenix, Inc. (ZGNX) Stock” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/life-sciences-maste-perceptive-buys-300000-shares-of-zogenix-inc-zgnx-stock/1609024.html.

Several hedge funds and other institutional investors have recently made changes to their positions in ZGNX. Nationwide Fund Advisors lifted its stake in shares of Zogenix by 29.5% in the first quarter. Nationwide Fund Advisors now owns 18,748 shares of the company’s stock valued at $203,000 after purchasing an additional 4,266 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Zogenix by 4.6% in the first quarter. Bank of New York Mellon Corp now owns 103,459 shares of the company’s stock valued at $1,123,000 after purchasing an additional 4,583 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Zogenix by 43.6% in the first quarter. Ameriprise Financial Inc. now owns 229,134 shares of the company’s stock valued at $2,486,000 after purchasing an additional 69,552 shares during the period. American International Group Inc. lifted its stake in shares of Zogenix by 7.1% in the first quarter. American International Group Inc. now owns 15,278 shares of the company’s stock valued at $166,000 after purchasing an additional 1,010 shares during the period. Finally, California Public Employees Retirement System lifted its stake in shares of Zogenix by 100.0% in the first quarter. California Public Employees Retirement System now owns 115,500 shares of the company’s stock valued at $1,329,000 after purchasing an additional 57,750 shares during the period. Hedge funds and other institutional investors own 87.21% of the company’s stock.

ZGNX has been the subject of a number of recent analyst reports. ValuEngine raised shares of Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Zacks Investment Research cut shares of Zogenix from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. BidaskClub cut shares of Zogenix from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. Mizuho reaffirmed a “buy” rating and issued a $51.00 price objective (up previously from $28.00) on shares of Zogenix in a report on Friday, September 29th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $26.00 target price on shares of Zogenix in a research note on Monday, June 26th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $40.00.

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.